HK1216299A1 - 表徵醋酸格拉替雷相关的药品 - Google Patents

表徵醋酸格拉替雷相关的药品 Download PDF

Info

Publication number
HK1216299A1
HK1216299A1 HK16104285.8A HK16104285A HK1216299A1 HK 1216299 A1 HK1216299 A1 HK 1216299A1 HK 16104285 A HK16104285 A HK 16104285A HK 1216299 A1 HK1216299 A1 HK 1216299A1
Authority
HK
Hong Kong
Prior art keywords
glatiramer acetate
drug product
characterizing
drug
acetate related
Prior art date
Application number
HK16104285.8A
Other languages
English (en)
Chinese (zh)
Inventor
Schwartz Rivka
Bakshi Shlomo
Daniel FOWLER Kevin
George TOWFIC Fadi
Michael FUNT Jason
James ZESKIND Benjamin
Artomov Maksym
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1216299(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1216299A1 publication Critical patent/HK1216299A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16104285.8A 2013-01-04 2014-01-02 表徵醋酸格拉替雷相关的药品 HK1216299A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361749228P 2013-01-04 2013-01-04
US61/749,228 2013-01-04
US201361819481P 2013-05-03 2013-05-03
US61/819,481 2013-05-03
PCT/US2014/010103 WO2014107533A2 (en) 2013-01-04 2014-01-02 Characterizing a glatiramer acetate related drug product

Publications (1)

Publication Number Publication Date
HK1216299A1 true HK1216299A1 (zh) 2016-11-04

Family

ID=51061235

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104285.8A HK1216299A1 (zh) 2013-01-04 2014-01-02 表徵醋酸格拉替雷相关的药品

Country Status (17)

Country Link
US (1) US20140193827A1 (enExample)
EP (1) EP2941274A4 (enExample)
JP (1) JP2016504039A (enExample)
KR (1) KR20150111945A (enExample)
CN (1) CN105228651A (enExample)
AU (1) AU2014204043A1 (enExample)
BR (1) BR112015016169A2 (enExample)
CA (1) CA2896957A1 (enExample)
CL (1) CL2015001915A1 (enExample)
EA (1) EA201591251A1 (enExample)
HK (1) HK1216299A1 (enExample)
IL (2) IL239692A0 (enExample)
MX (1) MX2015008754A (enExample)
PE (1) PE20151980A1 (enExample)
SG (1) SG11201505210RA (enExample)
WO (1) WO2014107533A2 (enExample)
ZA (1) ZA201505367B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
CN105377308B (zh) 2013-03-14 2019-07-26 迈兰公司 醋酸格拉替雷响应生物标志物mRNA效力测定
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9995734B2 (en) 2013-10-24 2018-06-12 Mylan Inc. Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
WO2017087866A1 (en) 2015-11-20 2017-05-26 Grand Valley State University Nato3 mutant polypeptides and uses thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
JP7276664B2 (ja) * 2016-11-11 2023-05-18 ロングエバーオン インコーポレイテッド 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
CN115044684A (zh) * 2022-06-22 2022-09-13 四川大学华西医院 lcn2基因作为生物标记物在检测Stat5基因是否缺失中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429374B2 (en) * 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
WO2004028339A2 (en) * 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
JP2009509142A (ja) * 2005-09-19 2009-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 調節性Ｔ細胞機能をモジュレート（ｍｏｄｕｌａｔｅ）し得るＧＰＲ８３アゴニストおよびＧＰＲ８３アンタゴニストを同定するための方法
US8753833B2 (en) * 2007-06-21 2014-06-17 Momenta Pharmaceuticals, Inc. Copolymer assay
EP2365825A1 (en) * 2008-11-18 2011-09-21 Crossbeta Biosciences B.V. Cross-beta structures as carriers in vaccines
NZ598661A (en) * 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy

Also Published As

Publication number Publication date
CL2015001915A1 (es) 2016-11-11
BR112015016169A2 (pt) 2017-07-11
EA201591251A1 (ru) 2016-05-31
KR20150111945A (ko) 2015-10-06
IL252547A0 (en) 2017-07-31
IL239692A0 (en) 2015-08-31
SG11201505210RA (en) 2015-07-30
EP2941274A4 (en) 2016-11-16
PE20151980A1 (es) 2016-01-15
ZA201505367B (en) 2016-11-30
MX2015008754A (es) 2016-04-11
WO2014107533A2 (en) 2014-07-10
EP2941274A2 (en) 2015-11-11
CN105228651A (zh) 2016-01-06
US20140193827A1 (en) 2014-07-10
WO2014107533A3 (en) 2015-01-29
AU2014204043A1 (en) 2015-08-13
CA2896957A1 (en) 2014-07-10
JP2016504039A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
WO2014107533A3 (en) Characterizing a glatiramer acetate related drug product
EP3392337A4 (en) GENETIC CHANGE OF NON-HUMAN ORGANISM, EGGS, BURIED EGGS AND METHOD OF MODIFYING TARGET GENES
EP4447066A3 (en) Insulin delivery system with risk based set points
EP3260539A4 (en) Method for transferring cas9 mrna into mammalian fertilized egg by electroporation
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
MX2018013810A (es) Composiciones y metodos para silenciar la expresion genetica.
WO2014160661A3 (en) Systems and methods for the targeted production of a therapeutic protein within a target cell
EP3342858A4 (en) ROR1-POSITIVE MESENCHYMAL STEM CELLS AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREOF, AND METHOD FOR PREVENTING OR TREATING DISEASES USING SAID ROR1 POSITIVE MESENCHYMAL STEM CELLS
EP3307164A4 (en) Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same
EP3608400A4 (en) CELL POPULATION WITH MESENCHYMAL STEM CELLS, METHOD OF MANUFACTURING THEREFORE AND PHARMACEUTICAL COMPOSITION
WO2014022826A3 (en) Biomarker associated with risk of melanoma reoccurrence
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
WO2011163566A3 (en) Methods of treating patients with immune-related diseases
EP3170892A4 (en) Method for enhancing activity of laminin fragment cell culture substrate
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
EP3279318A4 (en) Human serum albumin-containing culture medium for growth of neural stem cells
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same
EP3868863A4 (en) CELL CULTURE SUBSTRATE, METHOD FOR PREPARING A CELL CULTURE SUBSTRATE, AND METHOD FOR PREPARING SPHEROIDS
EP3258264A4 (en) Method for quantifying biological material, pathological diagnosis support system and program
WO2016004250A3 (en) Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
MX2022003399A (es) Metodo basado en celulas para determinar la potencia de la defibrotida.
WO2014001422A3 (en) Toll-like receptors and immunostimulatory oligonucleotides
MY176569A (en) Method of removing dna from biotechnological products
MX2016014628A (es) Metodo para expandir las celulas madre adultas de sangre entera.